98%
921
2 minutes
20
Wireless phones (both mobile and cordless) emit not only radiofrequency (RF) electromagnetic fields (EMF) but also extremely low frequency (ELF) magnetic fields, both of which should be considered in epidemiological studies of the possible adverse health effects of use of such devices. This paper describes a unique algorithm, developed for the multinational case-control MOBI-Kids study, that estimates the cumulative specific energy (CSE) and the cumulative induced current density (CICD) in the brain from RF and ELF fields, respectively, for each subject in the study (aged 10-24 years old). Factors such as age, tumour location, self-reported phone models and usage patterns (laterality, call frequency/duration and hands-free use) were considered, as was the prevalence of different communication systems over time. Median CSE and CICD were substantially higher in GSM than 3G systems and varied considerably with location in the brain. Agreement between RF CSE and mobile phone use variables was moderate to null, depending on the communication system. Agreement between mobile phone use variables and ELF CICD was higher overall but also strongly dependent on communication system. Despite ELF dose distribution across the brain being more diffuse than that of RF, high correlation was observed between RF and ELF dose. The algorithm was used to systematically estimate the localised RF and ELF doses in the brain from wireless phones, which were found to be strongly dependent on location and communication system. Analysis of cartographies showed high correlation across phone models and across ages, however diagonal agreement between these cartographies suggest these factors do affect dose distribution to some level. Overall, duration and number of calls may not be adequate proxies of dose, particularly as communication systems available for voice calls tend to become more complex with time.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.envint.2022.107189 | DOI Listing |
BMC Proc
August 2025
Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Drie Eikenstraat 663, 2650, Edegem, Belgium.
The human papillomavirus (HPV) Prevention and Control Board organized a meeting to explore effective strategies for accelerating the elimination of HPV-related cancers, starting from WHO's cervical cancer elimination campaign targets-vaccination of 90% of girls by age 15, two HPV screenings with a high-performance test for 70% of women between 35-45 years, and 90% treatment and care of women with cervical disease. Nevertheless, the global HPV vaccination coverage remains low (~ 30%), as does screening coverage, with only 24% (48/139) of programmes utilising recommended high-performance tests (such as HPV testing). The meeting explored various strategies, including the extension of vaccination for women at older ages.
View Article and Find Full Text PDFJ Antimicrob Chemother
August 2025
Pharmacokinetics and Clinical Pharmacy Laboratory, University of Bordeaux Bordeaux 33000, France.
Background: Optimal antimicrobial drug exposure in the lung is required for ensuring successful treatment of community-acquired pneumonia (CAP). Little is known about the intrapulmonary pharmacokinetics (PK) of ceftobiprole when administered by continuous infusion (CI).
Objective: To determine the PK of high doses (3 g/day) CI of ceftobiprole in the plasma and epithelial lining fluid (ELF) in mechanically ventilated patients with CAP.
Background: The newly identified small molecule ISFP10 has demonstrated the ability to inhibit fungal phosphoglucomutases (PGM), leading to decreased fungal growth and survival. Exhibiting 50 times greater selectivity for fungal PGM compared to the human homolog, ISFP10 shows promise as a broad-spectrum antifungal and a candidate for preliminary testing in rodent models of fungal infections, including Pneumocystis pneumonia (PCP). In preparation for targeted and relevant administration of the drug in fungal mouse models of infection, the current study describes the maximum-tolerated-dose (MTD) and pharmacokinetics (PK) of ISFP10 in mice.
View Article and Find Full Text PDFMed Phys
July 2025
Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Background: Compared with intensity modulated proton therapy (IMPT), proton arc treatment (PAT) employs an increased number of gantry angles, potentially reducing healthy tissues doses, especially for complex target geometries found in oropharyngeal cancer (OPC) treatment. PAT plans can be optimized with algorithms, based either on "static" gantry position or "dynamic" gantry movement during dose delivery. Recent results have shown target coverage may suffer more from inter-fraction patient anatomical- and setup changes In PAT than IMPT.
View Article and Find Full Text PDFJ Pediatr Pharmacol Ther
June 2025
Skaggs School of Pharmacy and Pharmaceutical Sciences (NT, DH, THD, AS, LH, JL), University of California at San Diego, La Jolla, CA.
Objective: Since 2011, Ampicillin (AMP) has been recommended as the parenteral antibiotic of choice for pediatric community-acquired pneumonia (CAP), but ceftriaxone (CRO) is recommended for unvaccinated children and those with complicated CAP. Using penicillin and CRO susceptibility data for pneumococcus, we evaluated the adequacy of currently recommended doses of AMP and CRO.
Methods: With nonlinear mixed-effects modeling v7.